Last reviewed · How we verify
ARCT-810
ARCT-810 is a self-amplifying RNA (saRNA) therapeutic that encodes a secreted form of arginase-1 to modulate immune responses in cancer.
ARCT-810 is a self-amplifying RNA (saRNA) therapeutic that encodes a secreted form of arginase-1 to modulate immune responses in cancer. Used for Advanced solid tumors (Phase 2 development).
At a glance
| Generic name | ARCT-810 |
|---|---|
| Sponsor | Arcturus Therapeutics, Inc. |
| Drug class | Self-amplifying RNA (saRNA) therapeutic |
| Target | Arginase-1 (ARG1) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
ARCT-810 delivers self-amplifying RNA that produces arginase-1, an enzyme that depletes arginine in the tumor microenvironment. By reducing arginine availability, the drug suppresses T cell function and promotes an immunosuppressive state, potentially enhancing anti-tumor immunity through immune modulation. This approach leverages RNA technology to achieve localized protein production with potential systemic effects.
Approved indications
- Advanced solid tumors (Phase 2 development)
Common side effects
- Injection site reactions
- Fever
- Fatigue
Key clinical trials
- Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810 (PHASE2)
- A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD (PHASE2)
- Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency (PHASE1)
- Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARCT-810 CI brief — competitive landscape report
- ARCT-810 updates RSS · CI watch RSS
- Arcturus Therapeutics, Inc. portfolio CI